Articles dans des revues avec comité de lecture (402)
  1. 349. Awada, A., Mano, M. S., Hendlisz, A., & Piccart-Gebhart, M. (2004). New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert review of anticancer therapy, 4(1), 53-60. doi:10.1586/14737140.4.1.53
  2. 350. Awada, A., & Klastersky, J. (2004). Ovarian cancer: State of the art and future directions. European journal of gynaecological oncology, 25(6), 673-676.
  3. 351. Awada, A. (2004). Angiogenesis inhibitors: a breakthrough in the treatment of solid cancers. The interface oncology & hematology, 14, 3-4.
  4. 352. Mano, M. S., Awada, A., Minisini, A., Atalay, G., Dal Lago, L., Cardoso, F., & Piccart-Gebhart, M. (2004). Remaining controversies in the upfront management of advanced ovarian cancer. International journal of gynecological cancer, 14(5), 707-720. doi:10.1111/j.1048-891X.2004.014502.x
  5. 353. Awada, A., Mano, M. S., Piccart-Gebhart, M., Cardoso, F., & Dal Lago, L. (2004). The dosing, schedule and route of chemotherapy in gynaecological cancers. CME journal of gynecologic oncology, 9, 73-80.
  6. 354. Awada, A., Cardoso, F., Atalay, G., Giuliani, R., Mano, M. S., & Piccart-Gebhart, M. (2003). The pipeline of new anticancer agents for breast cancer treatment in 2003. Critical reviews in oncology/hematology, 48(1), 45-63.
  7. 355. Atalay, G., Cardoso, F., Awada, A., & Piccart-Gebhart, M. (2003). Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Annals of oncology, 14(9), 1346-1363. doi:10.1093/annonc/mdg365
  8. 356. Awada, A., Thödtmann, R., Piccart-Gebhart, M., Wanders, J., Schrijvers, A. H. G. J., Von Broen, I.-M., Hanauske, A.-R., & EORTC-ECSG phase I study, (2003). An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours. European journal of cancer, 39(6), 742-747.
  9. 357. Pivot, X., Awada, A., Gedouin, D., Kerger, J., Rolland, F., Cupissol, D., Caponigro, F., Comella, G., Lopez-Pousa, J. J., Guardiola, E., Giroux, B., Gérard, B., & Schneider, M. (2003). Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer. Annals of oncology, 14(3), 373-377.
  10. 358. Awada, A. (2003). Relapsing ovarian cancer: selection of the therapeutic agent. UpToDate in Oncology, 2.
  11. 359. Vereecken, P., Mathieu, A., Laporte, M., Petein, M., Velu, T., Awada, A., & Heenen, M. (2003). Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod. Dermatology, 206(3), 279-280. doi:10.1159/000068901
  12. 360. Piccart-Gebhart, M., Floquet, A., Scarfone, G., Willemse, P. H. B., Emerich, J., Vergote, I., Giurgea, L., Coens, C., Awada, A., & Vermorken, J. B. (2003). Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. International journal of gynecological cancer, 13 Suppl 2, 196-203.
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 40 Suivant >>